Inhibition of STAT3 by S3I ‐201 suppress peritoneal fibroblast phenotype conversion and alleviate peritoneal fibrosis
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.18381 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Qianhui Song und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China. Hauptthemen laut MEDLINE: Aminosalicylic Acids, Fibroblasts, Peritoneal Fibrosis, Phenotype. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Municipal Education Commission-Gaofeng Clinical Medicine, National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Peritoneal fibrosis is a common pathological response to long‐term peritoneal dialysis (PD) and a major cause for PD discontinuation. Understanding the cellular and molecular mechanisms underlying the induction and progression of peritoneal fibrosis is of great interest. In our study, in vitro study revealed that signal transducer and activator of transcription 3 (STAT3) is a key factor in fibroblast activation and extracellular matrix (ECM) synthesis. Furthermore, STAT3 induced by IL‐6 trans‐signalling pathway mediate the fibroblasts of the peritoneal stroma contributed to peritoneal fibrosis. Inhibition of STAT3 exerts an antifibrotic effect by attenuating fibroblast activation and ECM production with an in vitro co‐culture model. Moreover, STAT3 plays an important role in the peritoneal fibrosis in an animal model of peritoneal fibrosis developed in mice. Blocking STAT3 can reduce the peritoneal morphological changes induced by chlorhexidine gluconate. In conclusion, our findings suggested STAT3 signalling played an important role in peritoneal fibrosis. Therefore, blocking STAT3 might become a potential treatment strategy in peritoneal fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
- Shanghai Center for Peritoneal Dialysis Research, Shanghai, People's Republic of China.
ORCID-Profile: Han Li
Förderung
- Shanghai Municipal Education Commission-Gaofeng Clinical Medicine
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Song, Q., Li, H., Yan, H., Yu, Z., Li, Z., Yuan, J., Jiang, N., Ni, Z., Gu, L., & Fang, W. (2024). Inhibition of STAT3 by S3I ‐201 suppress peritoneal fibroblast phenotype conversion and alleviate peritoneal fibrosis. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18381
Vancouver
Song Q, Li H, Yan H, Yu Z, Li Z, Yuan J, et al. Inhibition of STAT3 by S3I ‐201 suppress peritoneal fibroblast phenotype conversion and alleviate peritoneal fibrosis. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.18381
BibTeX
@article{Song2024,
author = {Song, Qianhui and Li, Han and Yan, Hao and Yu, Zanzhe and Li, Zhenyuan and Yuan, Jiangzi and Jiang, Na and Ni, Zhaohui and Gu, Leyi and Fang, Wei},
title = {Inhibition of STAT3 by S3I ‐201 suppress peritoneal fibroblast phenotype conversion and alleviate peritoneal fibrosis},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.18381}
}
EUVIMED